In Vivo Transfer of Intracellular Labels from Locally Implanted Bone Marrow Stromal Cells to Resident Tissue Macrophages by Pawelczyk, Edyta et al.
In Vivo Transfer of Intracellular Labels from Locally
Implanted Bone Marrow Stromal Cells to Resident Tissue
Macrophages
Edyta Pawelczyk
1*, Elaine K. Jordan
1, Arun Balakumaran
2, Aneeka Chaudhry
1, Nicole Gormley
3, Melissa
Smith
1, Bobbi K. Lewis
1, Richard Childs
3, Pamela G. Robey
2, Joseph A. Frank
1,4
1Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, 2National Institute of Dental and
Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America, 3National Heart, Lung and Blood Institute, National Institutes of Health,
Bethesda, Maryland, United States of America, 4National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, United
States of America
Abstract
Intracellular labels such as dextran coated superparamagnetic iron oxide nanoparticles (SPION), bromodeoxyuridine (BrdU)
or green fluorescent protein (GFP) are frequently used to study the fate of transplanted cells by in vivo magnetic resonance
imaging or fluorescent microscopy. Bystander uptake of labeled cells by resident tissue macrophages (TM) can confound
the interpretation of the presence of intracellular labels especially during direct implantation of cells, which can result in
more than 70% cell death. In this study we determined the percentages of TM that took up SPION, BrdU or GFP from
labeled bone marrow stromal cells (BMSCs) that were placed into areas of angiogenesis and inflammation in a mouse
model known as Matrigel
TM plaque perfusion assay. Cells recovered from digested plaques at various time points were
analyzed by fluorescence microscopy and flow cytometry. The analysis of harvested plaques revealed 5% of BrdU
+,5 – 1 0 %
of GFP
+ and 5–15% of dextran
+ macrophages. The transfer of the label was not dependent on cell dose or viability.
Collectively, this study suggests that care should be taken to validate donor origin of cells using an independent marker by
histology and to assess transplanted cells for TM markers prior to drawing conclusions about the in vivo behavior of
transplanted cells.
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Introduction
During the past few years, stem cell therapy has emerged as a
promising alternative for treatment of various incurable diseases.
Among many stem cell types, human bone marrow stromal cells
(BMSCs) appear to hold a great advantage because they are easily
obtained, propagated in culture and maintain genetic stability.
BMSCs also have the potential for multi lineage differentiation to
make bone, marrow adipocytes and hematopoietic supporting
stroma. [1]. BMSCs can down-regulate several functions of
immune cells, in addition to promoting survival of damaged cells
and tissues through paracrine factors, possibly under the guidance
of environmental cues [2–4]. BMSCs can also serve as cellular
vehicles for the delivery of therapeutic proteins based on their
ability to preferentially home to injured and inflamed tissues [5–7].
Thus, BMSCs clinical applications supported by preclinical results
in different animal models are becoming a reality.
BMSCs are usually delivered either by intravenous injection or
by direct implantation into target tissue. To track the fate of these
cells in both clinical studies and animal models, cell labeling
techniques such as bromodeoxyuridine (BrdU), green fluorescent
protein (GFP) or superparamagnetic iron oxide nanoparticle
(SPION) labeling, are being developed for tracking implanted
cells on histological examimation, or in vivo visualization by
noninvasive magnetic resonance imaging (MRI).
BrdU is a thymidine analogue that incorporates into DNA of
dividing cells during the S phase of the cell cycle [8]. It has been
widely used in various animal models to track migration and
differentiation of transplanted cells by autopsy and two-photon
microscopy [9–13]. In particular, BrdU labeling is currently the
most commonly used method for studying neurogenesis in adult
brain [14]. The introduction of GFP has revolutionized the field of
cell biology and fluorescence microscopy [15]. GFP is a naturally
fluorescent protein, originally cloned from jellyfish, Aequoria victoria
that can be expressed in any species, in which genetic
manipulation is possible. It is extensively used in animal models,
in transplantation studies to determine the fate of transplanted
cells, as well as for studying various biological processes.
BMSCs have also been more recently labeled after complexing
with two FDA approved agents, ferumoxides (Fe), a dextran-
coated SPION and protamine sulfate (Pro) to facilitate monitoring
by magnetic resonance imaging (MRI) or Prussian blue staining of
tissues [16–19]. MRI-based tracking of cells labeled with
ferumoxides allows for non-invasive in vivo detection and
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6712longitudinal assessment of implanted cells [20]. Fe-Pro labeled
cells appear as hypointense regions on MR images and thus can be
distinguished from the surrounding tissue.
A concern with the use of markers (BrdU, SPION or GFP) to
label cells is that the tag may be transferred to local, endogenous
bystander cells, such as tissue macrophages, especially in areas of
damage and inflammation, potentially confounding the interpreta-
tion of microscopy or cellular imaging. This is of particular
importance in direct implantation of BMSCs into target tissues,
which canresult in50% to80%cellsundergoing cell death [21–23].
Multiple reports have cautioned against over-interpretation of
results of labeled transplanted cells to host cells, though there has
been a dearth of reports quantifying the actual number of activated
tissue macrophages engulfing the markers or marked cells [24–29].
Recently, Pawelczyk et al [30] in an in vitro study showed BrdU or
SPION transferred to 10–20% of activated macrophages. Whether
similar results would occur in vivo is unknown.
Our objective was to determine the percentages of host tissue
macrophages that took up cellular labels, BrdU, GFP and SPION
from labeled BMSCs in an in vivo localized model of angiogenesis
and inflammation. Quantifying the percentage of macrophages that
incorporate GFP, SPION or BrdU from viable or dead cells will aid
in the interpretation of transplantation studies with labeled cells.
Results
Lentiviral transduction of BMSCs and labeling with BrdU
and superparamagnetic iron oxide nanoparticles
Isolated human and mouse BMSCs were characterized, as
previously published, by FACS, and for their potential for
osteogenic, adipogenic, and chondrogenic differentiation in in vitro
assays using specific induction media (data not shown) [1].
Lentiviral transduction resulted in ,60% of hBMSCs expressing
GFP. Only cell sorted GFP positive cells were used in animal
experiments. Incubation of human or mouse BMSCs with BrdU
resulted in ,70% of cells being labeled as assessed by FACS.
Prussian blue staining of Fe-Pro labeled mouse or human BMSCs
revealed abundant uptake of the Fe-Pro complex into the
cytoplasm in approximately 100% of cells. Representative
microphotographs of Fe-Pro, GFP and BrdU labeled human
BMSCs are presented in Figure 1. The iron content of Fe-Pro
labeled BMSCs was 29.660.45 picogram per cell and was similar
to the previously published studies [16].
BrdU uptake by macrophages infiltrating Matrigel
TM
plaque
To determine how often exogenous intracellular labels from
implanted BMSCs transfer or get taken up by infiltrating tissue
macrophages in areas of inflammation, a modified Matrigel
TM
plaque perfusion assay was used (Figure 2). Matrigel
TM plaques
(MPs) were prepared by mixing Matrigel
TM with a cocktail
composed of growth factors, chemokines, LPS and labeled
BMSCs, and then implanted subcutaneously into mice [31–33].
The number of live BMSCs implanted was chosen based on our
and others previously published studies [30,34]. Based on the
hematoxylin and eosin (H& E) staining of the MPs sections, as
early as day seven post-implantation, we observed new vessels
being formed (Figure 2). To determine the type of cells migrating
into the plaques, MPs harvested on day 7, 10 and 14 post-
implantation were digested and analyzed by FACS and immuno-
histochemistry techniques. The propidium iodide (PI) staining of
MPs showed no dead cells were detected. The FACS analysis
revealed cells expressing endothelial marker CD31, abundant
presence of CD45
+ positive cells including high levels of CD11b
+
or F4/80
+ cells and low numbers of CD3
+ lymphocytes (Figure 2
and 3). Live and labeled human BMSCs that were originally
implanted were detected based on CD29 staining (Figure 3). Flow
cytometry analysis of cells recovered from digested plaques
containing xenogeneic, human BrdU-labeled BMSCs showed that
an average 5% of macrophages were CD11b
+ BrdU
+ (5.7%63.03
on day 7, 5.4%62.49 on day 10 and 5.8%62.91 on day 14,
p=not significant, between time points) (Figure 4A and 4B). When
we analyzed the plaques containing BrdU- labeled syngeneic,
mouse BMSCs, only 1.7%60.68 of CD11b
+ BrdU
+ cells were
found on day 7, 0.7%60.49 on day 10 and 0.98%60.58 (p=not
significant, between time points) were CD11b
+ BrdU
+ two weeks
after implantation (Figure 4C). The CD11b
+ BrdU
+ cells were
visualized on cytospins and frozen sections under fluorescence
microscope (Figure 4D and 4E). The percentage of CD11b
+
BrdU
+ cells was comparable to FACS results.
GFP uptake by macrophages infiltrating Matrigel
TM
plaque
To assess the percentage of tissue macrophages taking up
endogenous label, human BMSCs were transduced with a
lentivirus encoding a GFP transgene. The FACS analysis of MP
containing GFP- labeled hBMSCs revealed a trend of increasing
frequency of CD11b
+ GFP
+ cells over time (4.5%62.54 on day 7,
4.8%62.17 on day 10 and 10.1%63.5 on day 10) (Figure 5A and
5B). There was a statistically significant increase in the percentage
of CD11b
+ GFP
+ cells found between day 7 and day 14 (p=0.024
and day 10 and 14 (p=0.021) (Figure 5B). The CD11b
+ GFP
+
cells were visualized on cytospins and frozen sections using
fluorescence microscopy (Figure 5C and 5D). The percentage of
CD11b
+ GFP
+ cells was comparable to flow cytometry results.
Fe-Pro uptake by macrophages infiltrating Matrigel
TM
plaque
The in vivo model of localized inflammation and angiogenesis
associated with the MP perfusion assay was also used to determine
the percentage of tissue macrophages migrating into the plaque
and phagocytosing dextran coated iron oxide nanoparticles. Seven
days after implantation of plaques containing two million live Fe-
Pro labeled hBMSCs, 9.9%64.13 of cells were found to be
CD11b
+dextran (Dex)
+ (Figure 6A and 6B). Over time, there was
a decreasing trend in the percentage of CD11b
+Dex
+ cells found
on day 10 and 14 (8.5%63.16 and 6.7%61.91, respectively,
Figure 6B). The decrease was statistically significant between days
7 and 14 (p=0.006) and days 10 and 14 (p=0.022) (Figure 6B).
Implantation of MPs with a higher dose of live hBMSCs (10610
6
Fe-Pro labeled cells) resulted in similar trends, but with a slightly
Figure1. Labeling of human bone marrow stromal cells (BMSCs)
with BrdU, GFP and Fe-Pro. Representative fluorescent microscopy
images of BrdU – labeled hBMSCs stained with anti BrdU- FITC antibody
(A), GFP expressing hBMSCs after lentiviral transduction (B) and Prussian
Blue (PB) stained Fe-Pro labeled hBMSCs (C), magnification 40X.
doi:10.1371/journal.pone.0006712.g001
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2610
6 cells (Figure 6C). Flow cytometry analysis revealed
7.1%61.67 of CD11b
+ Dex
+ cells on day 7, 3.8%60.86 on day
10 and 2.7%60.26 on day 14 post-implantation (Figure 6C). We
also tested whether local injection into the already vascularized
plaque of two million live Fe-Pro labeled hBMSCs on day 7 after
implantation of the matrigel containing only growth factors,
chemokines and LPS as opposed to implantation of cells and MP
at the same time, would result in a different outcome. The analysis
of the plaques containing locally injected cells showed similar level
of uptake, of 7.8%61.08 of CD11b
+ Dex
+ cells seven days after
injection of cells as compared with 9.7%64.13 of CD11b
+ Dex
+
cells found in plaques harvested seven days after cells were injected
post MPs implantation (Figure 6D).
In the next experiment, we evaluated whether implanted dead
Fe-Pro labeled hBMSCs would more readily transfer the label.
Flow cytometry analysis of plaques implanted with 2 million dead
Fe-Pro labeled hBMSCs resulted in higher uptake of the label
when compared to the macrophage uptake of Fe-Pro from the
plaques with live Fe-Pro labeled hBMSCs (Figure 6E). We
observed 15.7%64.33 of CD11b
+ Dex
+ cells on day 7,
9.1%62.87 on day 10 and 13.6%63.35 14 days following MPs
implantation (Figure 6E). The statistically significant decrease in
the percentage of CD11b
+ Dex
+ cells were found between day 7
and 10 (p=0.012) and increase between day 10 and 14 (p=0.035)
(Figure 6E). When we compared the Fe-Pro uptake by
macrophages from dead and live Fe-Pro labeled hBMSCs, the
statistically significant increase in the uptake was observed on day
7 (p=0.012) and day 14 (p,0.001).
We next tested whether implantation of MPs with syngeneic
mouse BMSCs would result in lower uptake of the Fe-Pro by tissue
macrophages as seen in the case of BrdU uptake by macrophages
from BrdU labeled, syngeneic mouse BMSCs. Flow cytometry
revealed that seven days after implantation, MPs contained
7.6%64.43 of CD11b
+ Dex
+ cells (Figure 6F). On day 10, we
found 8.1%61.89, while on day 14, 4.5%61.39 of cells were
CD11b
+ Dex
+ (Figure 6F). The CD11b
+ Dex
+ cells were visualized
on cytospins and frozen sections by fluorescence microscopy
(Figure 7A and 7B) as well as by immuno-histochemical staining
(Figure 7C). The frequency of CD11b
+ Dex
+ as well as dextran
and Prussian blue positive macrophages was comparable to FACS
results.
The lack of difference in the level of Fe-Pro uptake by tissue
macrophages between xenogenic and syngeneic Fe-Pro labeled
BMSCs (Figure 6B vs Figure 6F) prompted us to investigate the
potential immuno-stimulatory properties of Fe-Pro in labeled cells.
Figure 2. Schema of modified Matrigel
TM plaque perfusion assay. Matrigel
TM plaques (MPs) containing labeled bone marrow stromal cells
(BMSCs), growth factors, chemokines and inflammatory molecules, are implanted into both flanks of 6-week-old 129/SvlmJ mice, and harvested at
various time points for flow cytometry and microscopy analysis. Note representative images of collected MPs and immunohistochemical stains
revealing neovasculature on H & E staining, iron-labeled cells on Prussian blue (PB) staining or the presence of F4/80 positive macrophages (brown
cells), magnification 20X.
doi:10.1371/journal.pone.0006712.g002
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alloreactive T-cells in vitro in mixed lymphocyte reaction (MLR)
assay [35]. Both the unlabeled control and Fe-Pro labeled
hBMSCs suppressed MLR allo-reactivity in a dose-dependent
manner (Figure 8). At the 1:1 responder (non-irradiated peripheral
blood mononuclear cells (PBMC) to hBMSCs ratio, the PBMC
induced stimulation index was lower with Fe-Pro labeled hBMSCs
compared to control unlabeled hBMSCs (22.0% vs 38.5%,
p=0.010) and there was a non-significant (p=0.08) trend towards
a lower stimulation index at the 1:0.1 ratio (36.9% vs 74.1%,
Figure 8A). There was no statistically significant difference in
suppression of mitogen stimulated PBMC proliferation by Fe-Pro
labeled BMSCs compared to unlabeled BMSCs (Figure 8B).
MRI findings demonstrated unilateral hypointense regions
corresponding to the area of MPs implanted with 2 million
labeled hBMSCs (Figure 9A and 9B). Flow cytometry analysis of
MPs imaged and harvested on day 14 post-implantation showed
8.5%61.2 CD11b
+ Dex
+ macrophages (Figure 9C).
Discussion
The major findings of the study are that the direct implantation
of GFP, BrdU or SPION –labeled BMSCs into a localized area of
inflammation can result in 5%–15% of the label being
incorporated into host tissue macrophages. A mouse model of
angiogenesis known as the Matrigel
TM plaque perfusion assay was
used and modified to simulate a controlled locally contained
inflammatory environment where labeled cells would be locally
transplanted into a site as a part of the cell therapy approach. The
addition of growth factors such as vascular endothelial growth
factor (VEGF-B) and angiopoietin-2 stimulated angiogenesis
within the MPs (Figure 1). LPS and two potent stimulators of
macrophages migration; chemokine MCP-1 and SDF-1 were also
mixed within the MP prior to implantation to stimulate migration
of macrophages and other cells into and out of the damaged and
inflamed localized region. Flow cytometry analysis of harvested
plaques revealed approximately 5% of BrdU
+, 5%–10% GFP
+
and 5%–15% Dex
+ macrophages. These in vivo findings are
consistent with our previously published in vitro study using a
modified Boyden Chamber model of inflammation, where we
observed approximately 10% BrdU from BrdU-labeled cells was
transferred into macrophages and about 15% of macrophages
were dextran positive and contained approximately10% of the
total iron load from BMSCs [30]. To the best of our knowledge,
this is the first in vivo study that provides the quantitative data on
the transfer of exogenous or endogenous labels from BMSCs to
host macrophages that are found in the inflamed tissues.
Recently, several published reports have indicated that
intracellular labels from BMSCs or other stem cells can be
transferred to host macrophages following direct transplantation of
labeled cells. Two studies by Amsalem et al and Terrovitis et al
used xenogeneic and syngeneic rat models of myocardial
infarction where they injected iron oxide- and/or b-galactosidase-
labeled rat or human BMSCs into the injured myocardium of
immuno-competent rats [21,22]. Using immuno-histochemical
staining, the authors showed that three to four weeks after
transplantation none of the labeled BMSCs could be detected with
most of the Prussian blue positive cells for iron being infiltrating
macrophages that participated in the rejection process. As a result,
the hypointense region in the myocardium on MRI could
represent a false positive for stem cells although the authors noted
animals that received unlabeled stem cells also contained Prussian
blue positive macrophages with the iron originating from local
hemorrhage. Van de Bos et al reported that hemosiderin 5 weeks
following myocardial reperfusion in the swine model resulted in a
decrease in signal intensity on MRI that could mimic intracardiac
Figure 3. Matrigel
TM plaque cell content harvested on day seven post-implantation. Flow cytometry histograms revealing live, propidium
iodide (PI) negative cells expressing CD31, CD45, CD11b and CD3. Human BMSCs were detected by staining for CD29. Green lines indicate unstained
cells, while pink lines cells stained with appropriate isotype antibodies.
doi:10.1371/journal.pone.0006712.g003
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endogenous iron from hemorrhage can lead to Prussian blue
positive macrophages within tissues. It is important to realize that
with time the hypointense signal intensity area within the heart or
other pathological tissue will decrease in areas as macrophages
metabolize the iron oxide or migrate out of the tissue [37–39]. In
other studies of direct transplantation of SPION labeled cells in
mouse models of myocardial infarction, the transfer of the label to
macrophages was reported to occur rarely [40–41]. In a severe
skeletal muscle injury model, Winkler et al reported that local
transplantation of SPION labeled autologous mesenchymal stem
cells (MSCs) into the injured rat muscle resulted in a transfer of
nanoparticles to ED-1 positive tissue macrophages based on
histological analysis [42]. Other reports have indicated that
ferumoxides can also be incorporated into the tissue macrophages
from labeled neural progenitor cells following transplantation of
labeled cells into the adult rat spinal cord as well as from
ferumoxides labeled – pancreatic islet cells following their
Figure 4. BrdU uptake by local infiltrating Matrigel
TM plaque macrophages from BrdU-labeled BMSCs. Representative flow cytometry
dot plots showing 2.9% of CD11b-PE and BrdU-FITC positive macrophages in MPs harvested seven days post-implantation (A), Bar graph showing the
mean percentage of BrdU
+ CD11b
+ cells in all MPs collected 7, 10 and 14 days after implantation of MPs containing 2610
6 xenogenic hBMSCs (B) and
2610
6 syngeneic mouse BMSCs (C). Note the uptake of BrdU by tissue macrophages was lower from syngeneic BrdU – labeled mouse BMSCs when
compared to xenogenic BrdU-labeled hBMSCs. Immunofluorescent detection of BrdU with anti-BrdU-FITC, CD11b with anti-mouse CD11b-Alexa Fluor
594 on cytospins of cells recovered from MPs seven days post-implantation (magnification 40X), (D). On the merged image, note cells only positive
for CD11b-Alexa Fluor 594 and macrophages positive for BrdU-FITC and CD11b-Alexa Fluor 594. Those cells are local macrophages that took up BrdU
from BrdU labeled hBMSCs. Immunofluorescent detection of BrdU with anti-BrdU-FITC, F4/80 with anti-mouse F4/80-Alexa Fluor 594 on frozen
sections of MPs seven days post-implantation (magnification 40X), (D). Cells positive for macrophage marker, F4/80, as well as BrdU are indicated by
arrows. Data are presented as a mean61 SD from 12 plaques.
doi:10.1371/journal.pone.0006712.g004
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The composition of the MPs contained 8.5% CD11b
+Dex
+ cells
determined by FACS indicating that these labeled cells did not
contribute significantly to the signal changes on MRI.
Burns et al [23] reported the transfer of BrdU or other
thymidine analogs from labeled multipotent adult progenitor cells
(MAPCs) to neurons or glia in the developing and adult brain.
Furthermore, a recent study by Molcanyi et al [29] demonstrated
in a fluid- percussion injury model, that GFP-transfected murine
embryonic stem cells, once implanted into the injured rat brain,
were phagocytosed by activated macrophages. Guzman et al
showed 15% of local tissue macrophages were positive for BrdU
following transplantation of BrdU tagged neural stem cells in a
stroke model [44]. Collectively, all mentioned studies caution on
the interpreting the results from pre-labeled transplanted cells to
host cells, but none have quantified the frequency of the transfer of
intracellular labels to host macrophages that phagocytosed the
label or labeled cells.
Figure 5. GFP uptake by local infiltrating Matrigel
TM plaque macrophages from GFP-labeled hBMSCs. Representative flow cytometry
dot plots showing 8.1% of CD11b-PE and GFP-FITC positive macrophages in MPs harvested ten days post-implantation (A), Bar graph showing the
mean percentage of CD11b
+ GFP
+ cells in all MPs collected 7, 10 and 14 days after implantation of MPs containing 2610
6 xenogenic hBMSCs (B) Note
gradual increase in the uptake of GFP by macrophages over time with statistically significant increase in the GFP uptake between day 7 and day 14
(p=0.024) and day 10 and day 14 (p=0.021). Immunofluorescent detection of GFP and CD11b with anti-mouse CD11b-Alexa Fluor 594 on cytospins
of cells recovered from MPs ten days post-implantation (magnification 40X), (C). On the merged image, note cell only positive for GFP and a
macrophage positive for GFP and CD11b-Alexa Fluor 594. Immunofluorescent detection of GFP and F4/80 with anti-GFP-Alexa 488 and anti-mouse
F4/80-Alexa Fluor 594 on frozen sections of MPs ten days post-implantation (magnification 40X), (D). Cells positive for GFP and macrophage marker,
F4/80, are indicated by arrows. Data are presented as a mean61 SD from 12–18 plaques.
doi:10.1371/journal.pone.0006712.g005
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with our previously published in vitro study provides an estimate to
aid in the interpretation of future transplantation studies. The
results suggest that direct transplantation studies with cells labeled
with BrdU, GFP or iron oxide nanoparticles should be rigorously
validated by injections of unrelated live or dead cells and staining
for markers expressed by local host cells such as tissue
macrophages. This may be of particular importance in studies
that involve direct injections of cells into highly inflamed or injured
tissues such as myocardial infarction, or proliferative environments
of central nervous system, where $90% of cells may die shortly
after implantation [21,23].
Our study showed that implantation of syngeneic BrdU-labeled
BMSCs resulted in a lower uptake of BrdU by mouse macrophages
compared to xenogenic hBMSCs. However, the uptake of SPION
by macrophages was equivalent after implantation of syngeneic
mouse Fe-Pro labeled BMSCs or xenogenic Fe-Pro-labeled
hBMSCs. Since we used immuno-competent mice, this observation
prompted us to testwhether SPION labeling may predispose labeled
cells to become more immunogenic and susceptible to an immune
attack. The results of MLR assay revealed that the suppression of
proliferation of alloreactive T-cells was surprisingly greater for Fe-
Pro labeled hBMSCs when compared to the level of suppression
achieved with unlabeled cells, indicating a possible decrease in
Figure 6. Fe-Pro uptake by local infiltrating Matrigel
TM plaque macrophages from Fe-Pro-labeled BMSCs. Representative flow
cytometry plots showing 7.5% of CD11b-PE and Dextran (Dex)-FITC positive macrophages in MPs harvested fourteen days post-implantation (A), Bar
graph showing the mean percentage of CD11b
+ Dex
+ cells in all MPs collected 7, 10 and 14 days after implantation of MPs containing 2610
6 Fe-Pro
labeled live xenogenic hBMSCs (B), 10610
6 Fe-Pro labeled live xenogenic hBMSCs (C), the mean percentage of CD11b
+ Dex
+ cells in all MPs
containing 2610
6 Fe-Pro labeled hBMSCs and collected on day 7 after implantation as comparted to local injection of 2610
6 Fe-Pro labeled hBMSCs
into already vascularized plaque and collecting it 7 days post-injection (D), bar graph showing the mean percentage of CD11b
+ Dex
+ cells in MPs
collected 7, 10 and 14 days after implantation of MPs containing 2610
6 dead Fe-Pro labeled hBMSCs (E) and 2610
6 syngeneic, live Fe-Pro labeled
mouse BMSCs (F). Note similar levels and a gradual decrease of Fe-Pro uptake by macrophages after implantation of live xenogenic Fe-Pro-labeled
hBMSCs or syngeneic mouse Fe-Pro labeled BMSCs. The uptake of Fe-Pro by macrophages from dead Fe-Pro labeled hBMSCs was higher as
compared to the Fe-Pro uptake from live Fe-Pro labeled hBMSCs.
doi:10.1371/journal.pone.0006712.g006
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difference in the level of SPION uptake from xenogenic Fe-Pro
labeled hBMSCs compared to syngeneic mouse labeled BMSCs can
be from greater immunosuppression of Fe-Pro labeled hBMSCs. In
comparison, the implantation of xenogenic cells resulted in a lower
immunoreactivity of the Fe-Pro labeled hBMSCs. Since clinical
relevance of these data is not clear, additional in vitro and in vivo
studies will be required to fully explain these results.
For this focal model of inflammation based on the MP perfusion
assay,thedoseofcellsimplantedintoMatrigel
TMplaques wasbased
on our previously published in vitro Boyden Chamber model of
inflammation [30]. Injection of higher doses such as ten million cells
resulted in a similar level of label uptake by tissue macrophages
compared to injecting two million cells. The implantation of dead
Fe-Pro labeled hBMSCs as well as comparing the injection of
labeled cells at the time of MPs implantation to direct injection of
labeled cells once the plaque was vascularized, resulted in no
difference in the level of Fe-Pro uptake.
In our previous study, we showed that less than 10% of the total
iron from Fe-Pro labeled BMSCs was found in activated
macrophages [30]. We concluded that the contribution of iron
containing macrophages to the generation of hypointense regions
observed on in vivo MRI was below the detection level. The results of
this study are in accordance with that observation. MR imaging of
MPs containing 2 million Fe-Pro labeled BMSCs showed no
contribution ofiron-containing tissuemacrophages tothegeneration
of signals on MRI. However, for studies on trans-differentiation,
such as mesenchymal or hematopoetic stem cells differentiating to
cells of other tissue like neurons or epithelial cells, interpretations
based on the uptake of the label can be misleading especially since a
very low percentage of cells are thought to change lineages and this
may well be from the macrophage uptake of labels [45–46].
Figure 7. Immunofluorescent and Prussian Blue (PB) staining of Fe-Pro uptake by local infiltrating Matrigel
TM plaque macrophages
from Fe-Pro-labeled BMSCs. Representative immunofluorescent images showing detection of dextran (Dex) with anti-Dex-FITC, CD11b with anti-
mouse CD11b-Alexa Fluor 594 on cytospins of cells recovered from MPs fourteen days post-implantation (magnification 40X), (A). On the merged
image, note cells only positive for CD11b-Alexa Fluor 594 and macrophages positive for Dex-FITC and CD11b-Alexa Fluor 594. Those cells are local
macrophages that took up Fe-Pro from Fe-Pro labeled hBMSCs. Immunofluorescent detection of Dex with anti-Dex-FITC, F4/80 with anti-mouse F4/
80-Alexa Fluor 594 on frozen sections of MPs fourteen days post-implantation (magnification 40X), (B). Cells positive for macrophage marker, F4/80,
as well as Dex are indicated by arrows. Immunohistochemical staining of MP sections showing colocalization of iron-positive cells (PB staining, blueo r
brown cells) and cells positive for macrophage marker, F4/80 (red cells) (C). Data are presented as a mean61 SD from 12–18 plaques.
doi:10.1371/journal.pone.0006712.g007
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tissue macrophages was based on the flowcytometry analysis of cells
stained with anti-dextran antibodies. We showed this technique to
be highly reproducible, and a reliable method of determining the
number of labeled BMSCs up to 4 days post-labeling. It is known
that dextran may begin detaching from the iron oxide crystal as
early as 24 hours after labeling depending on the size of the iron
oxide nanoparticles and the type of cells labeled [47]. Furthermore,
the behavior of SPION in labeled BMSCs is not known in the in vivo
setting. In this study, we analyzed cells from MPs harvested one and
two weeks post-implantation, therefore a limitation of this study
could be a potential underestimation of the number of Fe-Pro
labeled macrophages due to possible detachment of the dextran
molecules from iron oxide crystal surface. Since we were unable to
separate CD11b positive cells containing SPION from Fe-Pro
labeled BMSCs it was not possible to determine if there were
differences in the percentages of dextran positive from Prussian blue
positive macrophages.
In conclusion, our data shows that direct implantation of BrdU,
GFP or SPION labeled BMSCs into localized area of inflamma-
tion and angiogenesis can result in non-specific uptake of the label
by infiltrating local tissue macrophages and lead to over -
interpretation of the obtained results. Care should be taken to
validate by histology of transplanted cells for macrophage markers,
prior to drawing conclusions about the in vivo behavior of
transplanted cells. Our study, which quantified the percentage of
host bystander cells that up take the label from labeled BMSCs will
aid in the interpretation of future transplantation studies.
Materials and Methods
Ethics statement
Animal experiments were performed according to a protocol
approved by Clinical Center Animal Care and Use Committee
(ACUC) of National Institutes of Health.
Harvest and expansion of human and mouse bone
marrow stromal cells (BMSCs)
Human and mouse 129/SvlmJ bone marrow stromal cells
(BMSCs), a subset of which are multipotent skeletal stem cells,
Figure 8. Mixed lymphocyte reaction (MLR) with Fe-Pro labeled
hBMSCs. Bar graph showing the mean stimulation index (SI) for both,
Fe-Pro labeled and unlabeled hBMSCs suppress T-cell proliferation in
HLA mismatched MLR assay in response to alloreactive T-cells (A) and
following nonspecific mitogen stimulation with phytohemagglutinin
(PHA) (B). Control hBMSCs or Fe-Pro labeled hBMSCs were added at the
ratios of 1:1 or 0.1:1 of non-irradiated PBMCs (responders) which
proliferate in response to foreign histocompatibility antigens present
on irradiated PBMCs (stimulators). Note, both the unlabeled control and
Fe-Pro labeled hBMSCs suppressed MLR allo-reactivity in a dose-
dependent manner. At the 1:1 responder to hBMSCs ratio, the PBMC
induced stimulation index was significantly lower with Fe-Pro labeled
hBMSCs compared to control hBMSCs (p=0.010), NS=not significant.
doi:10.1371/journal.pone.0006712.g008
Figure 9. In vivo MRI T2 and T2* image of Matrigel
TMplaques (MPs) two weeks post-implantation. T2 weighted (A) and T2 * images (B)
images of a representative MP contanining 2610
6 Fe-Pro labeled hBMSCs (indicated by white dashed line). Corresponding flow cytometry dot plot
showing 8.5% of CD11b-PE and Dextran (Dex)-FITC positive macrophages in the imaged MPs (C).
doi:10.1371/journal.pone.0006712.g009
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details are found in the Supporting Information Text S1.
BMSCs transduction with lentivirus
Human BMSCs were transduced with a lentivirus encoding
copeod green fluorescent protein (copGFP) (pSIH1-siLuc-copGFP
lentivirus, System Biosciences, Mountain View, CA) by replacing
the medium with fresh medium containing viral particles and
incubating overnight at 37uC in a 95% air per 5% CO2
atmosphere. After overnight incubation, the media was replaced
and the cells were incubated for 48 hours. Flow cytometry was
used to evaluate the transduction efficiency of cells expressing the
GFP transgene and transduced cells were sorted using the MoFlow
cell sorter (Dako Cytomation, Fort Collins, CO).
Labeling of BMSCs with BrdU
After reaching 60% confluence, human and mouse BMSCs
were labeled with bromodeoxyuridine (BrdU) by adding 100 mgo f
BrdU (BD Biosciences, San Jose, CA) to culture flasks and
incubating for 4 days. After labeling, cells were washed three times
with sterile PBS, trypsinized and were then used in animal
experiments. The labeling efficiency was evaluated by flow
cytometry.
Labeling of BMSCs with Fe-Pro
Ferumoxides (Fe, Feridex IV, Berlex Laboratories, Wayne, NJ)
is a dextran coated SPIO nanoparticle approximately 120–
150 nm in size and is provided at a total iron content of
11.2 mg/ml. Protamine sulfate (Pro, American Pharmaceuticals
Partner, Schaumburg, IL), supplied at 10 mg/ml, was prepared as
a fresh stock solution of 1 mg/mL in sterile distilled water
immediately before labeling. Ferumoxides at a concentration of
100 mg/ml was added to a 50 ml conical tube containing serum-
free RPMI 1640 (Biosource, Camarillo, CA) with 25 mM HEPES,
MEM nonessential amino acids, sodium pyruvate, and L-
glutamine. Protamine sulfate was added to the solution at 6 mg/
ml and mixed for 2 minutes with intermittent hand shaking.
Culture media was aspirated from the flasks containing human
and mouse BMSCs and replaced with medium containing Fe-Pro
complexes. After 2 hours of incubation at 37uC, an equal amount
of relevant complete medium was added for a final concentration
of Fe to pro, 50 mg/ml to 3 mg/mL, respectively. Cells were
incubated overnight, approximately 16 hours, and washed three
times with sterile PBS containing 10 U/mL heparin sulfate
(American Pharmaceuticals Partner, Schaumburg, IL). Complete
medium was added to each flask and labeled cells were kept in
culture for 2 days to ensure all Fe-Pro complexes were
endocytosed and the label was not attached to cell surface. In
order to obtain dead cells, Fe-Pro labeled hBMSCs underwent 2–3
rounds of quick freeze/thaw cycles.
Prussian Blue Staining and Fe-Pro Labeling Efficiency
To visualize the iron within Fe-Pro labeled cells, Prussian blue
(PB) staining was performed. After 2 days post-labeling, BMSCs
were trypsinized and transferred to cytospin slides. Cells were fixed
with 4% glutaraldehyde, washed, and incubated for 30 minutes
with 2% potassium ferric-ferrocyanide (Perl’s reagent for staining,
Sigma, St. Louis, MO) in 3.7% hydrochloric acid. Cells were
washed again, counterstained with nuclear fast red and evaluated
for iron staining using light microscopy (Axioplan Imaging II;
Zeiss, Oberkochen, Germany) at X 40/0.75 objective lens and
Axiovision 4.4 software (Zeiss, Oberkochen, Germany). The
images were processed using Adobe Photoshop 7.0 (San Jose,
CA). Fe-Pro labeling efficiency was determined by manual
counting of PB stained and unstained cells using a Zeiss
microscope (Axioplan Imaging II, Zeiss, Oberkochen, Germany)
at X 100 magnification using an X 100/1.30 oil immersion
objective lens. The percentage of labeled cells was determined
from the average of 5 high-powered fields.
Matrigel
TM plaque perfusion assay
The Matrigel
TM plaque perfusion assay was designed as
previously described with modifications to simulate localized
model of inflammation [31–33]. Briefly, 0.5 ml of Matrigel
TM
(ECM gel from Engelbreth-Holm-Swarm murine sarcoma, Sigma-
Aldrich, St. Louis, MO) containing recombinant human protein
VEGF-B167 and recombinant human angiopoietin-2, both at the
dose of 500 ng/ml (both from R&D Systems, Minneapolis, MN),
mouse recombinant SDF-1 and MCP-1 at the dose of 500 ng/ml
(both from Peprotec, Rocky Hill, NJ), and lipopolisacharide (LPS)
at the dose of 100 ng/ml was mixed with 2610
6 or 10610
6
human or mouse BMSCs labeled with GFP, BrdU or SPIO
nanoparticles and incubated overnight at 37uC in a 95% air per
5% CO2 atmosphere. After overnight incubation, solidified
Matrigel
TM plaques (MPs) were injected or transplanted subcuta-
neously into both shaved and butadiene/alcohol prepped flanks of
6-week-old 129/SvlmJ mice (Charles River Laboratories, Inc.,
Wilmington, MA) under isoflurane anesthetized (2.5–3% isoflur-
ane with an oxygen flow rate of 2.5 liters/min), 6–9 mice per
group and time point. As controls, 4 mice in each group were
injected with Matrigel
TMand growth factors alone. As an
alternative experiment to implantation of Matrigel
TM containing
labeled cells, 6 mice were injected with Matrigel
TM and growth
factors only, and left for 7 days to allow the neovasculature to
develop. At day seven, 2610
6 human SPION labeled BMSCs
were locally injected into the plaque and left for an additional 7
days before removal.
On day 7, 10 and 14, the mice were euthanized and the skin of
the mouse was pulled back to expose MPs. Plugs were then
resected from surrounding connective tissue, placed into tubes
containing dispase (BD Biosciences, San Jose, CA), snap-frozen for
fluorescence microscopy, or fixed in 3.7% formaldehyde, embed-
ded in paraffin and sectioned for immunohistochemistry staining.
MPs were incubated with dispase for 2 hours at 37uC, then
homogenized and centrifuged at low speed for 10 minutes, washed
several times in PBS, resuspended in fresh RPMI medium and
recovered cells were counted using a hemocytometer.
Flow Cytometry Analysis (FACS)
Cells recovered from the plaques were fixed and permeabilized
with BD Cytofix/Cytoperm Plus
TM (with GolgiStop
TMcontaining
monensin) kit (BD Biosciences, San Jose, CA) according to
manufacturer’s instructions. Cells were stained for dextran, GFP
and CD11b using anti-dextran IgG1-FITC (Stem Cell Technol-
ogies Inc., Vancouver, Canada), anti-GFP-FITC (Millipore,
Billerica, MA) and anti- CD11b IgG2a-PE (BD Biosciences, San
Jose, CA) antibodies. The control experiments included unstained
cells and cells stained with isotype controls for each of the
antibodies. BrdU was detected using a FITC-BrdU Flow Kit (BD
Biosciences, San Jose, CA) according to manufacturer’s instruc-
tions.
In order to assess the cell content of the recovered plaques,
representative MPs were stained for mouse CD45 (leukocyte
common antigen), CD3 (lymphocytes), CD31 (endothelial cells)
and human CD29 to identify BMSCs. The following antibodies
were used: anti-human CD29- IgG2a-PE, anti –mouse CD31-
IgG2a-PE, anti-mouse CD45 - IgG1-FITC, anti- mouse CD-3
Label Uptake by Macrophages
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Cells were also stained with propidium iodide (PI). Stained cells
were analyzed by flow cytometry (FACS Calibur, Becton
Dickinson, Franklin Lakes, NJ). A total of 15,000 cells were
analyzed at the FL1, FL2 and FL3 detectors and the results were
presented as the mean percentage of CD11b
+ Dex
+, CD11b
+
GFP
+ or CD11b
+ BrdU
+ cells from each recovered MP.
Fluorescence Microscopy and Immunohistochemistry
Analysis
For fluorescence microscopy and immunohistochemical analysis
MPs were recovered and stained according to standard proce-
dures. The materials and methods are described in detail in
Supporting Information Text S1.
Mixed Lymphocyte reaction (MLR) assay
The ability of BMSCs to suppress alloreactive T-cells has
traditionally been assessed in vitro using a mixed lymphocyte
reaction (MLR) assay [35]. Therefore, we compared the
immunosuppressive properties of iron oxide labeled- hBMSC to
control hBMSCs using a conventional 5-day MLR assay.
Peripheral blood from two healthy, HLA-mismatched donors
was collected via apheresis. Ficoll-separated peripheral blood
mononuclear cells (PBMCs) were plated in a 96 well plate at
100,000 responder cells per well. Responder cells were either a) co-
cultured with 2500 cGy irradiated stimulator PBMCs at a 1:1 or b)
stimulated with the mitogen phytohemagglutinin (PHA). Control
hBMSCs or Fe-Pro labeled hBMSCs were added at the following
responder-BMSCs ratios: 1:0.1 or 1:1. Culture plates were
incubated for 5 days in a humidified 5% CO2 incubator at
37uC. On day 4 of the MLR, 1 mCi of
3H-thymidine (
3H-TdR)
was added to each well for 20 hours with T-cell proliferation
measured using a liquid scintillation counter. The data are
presented as stimulation index values calculated by using the
following formula: proliferation of responder PBMCs stimulated
by irradiated PBMCs (stimulators) or PHA and incubated with
control or Fe-Pro labeled hBMSCs/proliferation of PBMCs
stimulated by PBMCs or PHA alone. The experiments were
performed at least three times for each variable described.
Magnetic Resonance Imaging
Four 6-week-old 129/SvlmJ mice were implanted with MP
containing 2610
6 Fe-Pro labeled BMSCs or unlabeled cells and
MRI was performed on day 14-post implantation. The method-
ological details are found in the Supporting Information Text S1.
Statistics
The experiments were performed at least three times for each
variable described. Data are expressed as a mean6SD. The
statistically significant differences were detected using the Student t
test for unpaired data (2-tail) with significant p value,0.05 (Prism
4 Macintosh; GraphPad Software, Inc., San Diego, CA).
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0006712.s001 (0.05 MB
DOC)
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